Compare LGO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGO | IMUX |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 85.8M |
| IPO Year | 2007 | N/A |
| Metric | LGO | IMUX |
|---|---|---|
| Price | $1.23 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.30 | ★ $6.00 |
| AVG Volume (30 Days) | 561.5K | ★ 1.7M |
| Earning Date | 11-12-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $111,884,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $53.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $0.51 |
| 52 Week High | $2.70 | $1.39 |
| Indicator | LGO | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 57.63 |
| Support Level | $1.05 | $0.64 |
| Resistance Level | $1.24 | $0.72 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 90.81 | 84.72 |
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.